Pfizer executive admits COVID-19 vaccine was never tested to prevent transmission: 'This is scandalous'



In a shocking admission, a Pfizer executive on Monday stated that the company did not know if the COVID-19 mRNA vaccine it developed with BioNTech would prevent viral transmission before bringing it to market last year.

Janine Small, the president of international development markets for Pfizer, testified before the European Parliament's COVID-19 committee Monday on behalf of Pfizer CEO Dr. Albert Bourla, who was summoned by the committee but pulled out of his appointment.

During questions, Dutch Member of Parliament Rob Roos, a conservative and opponent of Europe's COVID-19 passports, asked Small whether Pfizer could provide lawmakers with evidence it believed the vaccine would prevent coronavirus transmission before bringing it to market.

"Was the Pfizer COVID vaccine tested on stopping the transmission of the virus before it entered the market?" Roos asked. "If not, please say it clearly. If yes, are you willing to share the data with this committee?”

In response, Small said Pfizer did not know that the vaccine would prevent transmission before bringing it to market.

“Regarding the question around, did we know about stopping immunization before it entered the market? No," she admitted.

"These, um, you know, we had to really move at the speed of science to really understand what is taking place in the market. And from that point of view, we had to do everything at risk,” Small said.

Following guidance from public health authorities, many governments in Europe and around the world implemented policies requiring people to show proof of COVID-19 vaccination in order to fully participate in public life. These "COVID passports" were issued on the premise that the vaccinated were protected from illness so that they could socialize with other people without risk of spreading the disease.

Roos, who along with a handful of other members of European Parliament objected to vaccination requirements, said in a video Tuesday that the justification for COVID passports "was always a lie."

"If you don't get vaccinated, you're anti-social! This is what the Dutch prime minister and health minister told us. You don't get vaccinated just for yourself, but also for others — you do it for all of society. That's what they said," Roos recounted. "Today, this turns out to be complete nonsense."

Roos said Small's admission that the vaccine was not tested to prevent transmission "removes the entire legal basis for the COVID passport. The COVID passport that led to massive institutional discrimination as people lost access to essential parts of society."

"I find this to be shocking, even criminal," Roos added.

\u201c\ud83d\udea8 BREAKING:\n\nIn COVID hearing, #Pfizer director admits: #vaccine was never tested on preventing transmission.\n\n"Get vaccinated for others" was always a lie.\n\nThe only purpose of the #COVID passport: forcing people to get vaccinated.\n\nThe world needs to know. Share this video! \u2935\ufe0f\u201d
— Rob Roos MEP \ud83c\uddf3\ud83c\uddf1 (@Rob Roos MEP \ud83c\uddf3\ud83c\uddf1) 1665479060

The mRNA vaccine developed by Pfizer-BioNTech was granted emergency use authorization in the United States on Dec. 11, 2020, and later granted Food and Drug Administration approval on August 23, 2021. The vaccine is marketed as Comirnaty and is used for the prevention of COVID-19 in individuals 12 years of age and older, though it is authorized for emergency use in children as young as five.

In granting an emergency use authorization to Pfizer in late 2020, the FDA wrote that there was no evidence that the vaccine prevents transmission of SARS-CoV-2 from person to person.

Public health officials, including the U.S. Centers for Disease Control and Prevention, maintain that COVID-19 vaccination significantly lowers the risk of severe illness, hospitalization, and death for those infected with COVID-19.

"Like all vaccines, COVID-19 vaccines are not 100% effective at preventing infection. Some people who are up to date with their COVID-19 vaccinations will get COVID-19 breakthrough infection," the CDC says. "However, staying up to date with your COVID-19 vaccinations means that you are less likely to have a breakthrough infection and, if you do get sick, you are less likely to get severely ill or die."

Prior to the vaccine's approval, Pfizer claimed that studies showed its vaccine was as much as 91.3% effective against COVID-19 and 100% effective in preventing infections in at least one study.

\u201cExcited to share that updated analysis from our Phase 3 study with BioNTech also showed that our COVID-19 vaccine was 100% effective in preventing #COVID19 cases in South Africa. 100%! https://t.co/E2ksTJSopU\u201d
— Albert Bourla (@Albert Bourla) 1617284815

Roos said that the Pfizer executive's admission that the vaccine was never tested for preventing transmission was "scandalous."

"Millions of people worldwide felt forced to get vaccinated because of the myth that 'you do it for others.' Now this turned out to be a cheap lie. This should be exposed."

Pfizer did not respond to a request for comment.

Over time, the vaccine has proved to have waning efficacy against mutating strains (Delta, Omicron, etc.) of the SARS-CoV-2 virus. Health officials have advocated for people to receive COVID-19 booster shots as breakthrough infections have become more common.

Still, officials have claimed, contrary to the evidence that COVID-19 vaccination will prevent infection. President Joe Biden in July 2021 stated, "You're not going to get COVID if you have these vaccinations." About a year later, he tested positive for the virus despite being fully vaccinated and up to date with booster shots.

Outgoing White House chief medical adviser Dr. Anthony Fauci, the government's go-to health spokesman during the pandemic, has also given conflicting statements on the vaccine's effectiveness. In May 2021, Fauci told CBS News that vaccinated people were a "dead end" for the virus, saying the likelihood a vaccinated person could transmit COVID was "very, very low."

"When you get vaccinated, you not only protect your own health and that of the family, but also you contribute to the community health by preventing the spread of the virus throughout the community,” Fauci said.

However, in August 2021, during the Delta wave, Fauci told Katie Couric that vaccinated people could still transmit the virus. "They’re either without symptoms or only mildly symptomatic,” he said. “So it’s less that it’s going to make the vaccinated person sick. It’s more that it’s going to allow the vaccinated person to transmit it to someone else who might get sick, like a vulnerable person in the family, an elderly individual, a child who’s unvaccinated.”

The point wasn't to prevent transmission, but rather reduce the severity of illness, Fauci explained at the time. "The vaccine is doing exactly what we wanted it to do,” he said. “It’s preventing people from getting seriously ill — that’s the reason why you get vaccinated.”

Pfizer vaccine's protection against Omicron drops as soon as three weeks after third dose: Study



The effectiveness of Pfizer and BioNTech's COVID-19 vaccine wanes rapidly against the Omicron variant, beginning to fade away as soon as three weeks after the second or third dose, a new study finds.

Researchers said that the antibody responses induced by a second and third dose of the vaccine were "transient" and that "additional booster doses may be necessary," although the vaccine still provides enough immunity to ward off hospitalization and death from COVID-19.

The Danish study, which was published in JAMA Network Open on Friday, examined 128 people who had received two or three doses of Pfizer/BioNTech's mRNA vaccine.

Scientists observed that the number of "neutralizing" antibodies induced by the vaccine that target the Omicron variant declined rapidly within weeks of taking the second and third shots. Antibodies attack the virus and stop it from replicating, which protects the body against infection and disease.

The study examined the antibody response in vaccinated patients to different strains of the coronavirus, including the original and Delta variant strains. Within four weeks of the second Pfizer/BioNTech dose, the concentration of Omicron-specific antibodies found in patients' blood was 14-fold lower than antibodies against the original virus strain.

Compared to the original and Delta variants, the proportion of Omicron-specific neutralizing antibodies fell "rapidly" from 76.2% four weeks after the second shot to 53.3% at weeks eight to 10, and then 19% at weeks 12 to 14, the researchers said.

After a third dose, Omicron-specific antibodies increased nearly 21-fold at week three and nearly 8-fold at week four, compared to antibody levels observed four weeks after the second dose.

However, antibody levels dropped between the third week and the eighth week after the third dose, with a 4.9-fold drop for the original strain, 5.6-fold for Delta, and 5.4 fold for Omicron observed.

This means that the number of antibodies the vaccine teaches the body to make to fight COVID-19 drops off as soon as four weeks after the second shot and three weeks after the third. Lower antibody levels offer less protection against the virus, which explains why people who have been fully vaccinated with two shots or have only had one booster may still get breakthrough Omicron infections.

The researchers say that additional booster shots may be needed to keep Omicron-specific antibody levels high and protect against disease, especially in older people.

Previous studies have shown that protection against infection offered by COVID-19 vaccines begins to wane after about six months. Older Americans, who are more vulnerable to severe disease, have been encouraged by public health officials to take vaccine booster shots to strengthen their antibody response to the virus.

According to U.S. Centers for Disease Control and Prevention data, about 69% of U.S. adults over age 65 have received a booster dose, while nearly 91% have completed their primary COVID-19 vaccination schedule.

The U.S. Food and Drug Administration in March authorized a second booster shot for Americans over the age of 50, citing evidence that suggested vaccine protection wanes over time and that older and immunocompromised people need additional protection offered by a fourth dose.